U.S. stock market update: Sonnet BioTherapeutics up 8.39%

U.S. Stock Market Midday Update

Sonnet BioTherapeutics rose 8.39%. Based on recent important news:

1. On June 8, the trading volume of Ruizhi Pharmaceuticals significantly increased, with an average daily trading growth of 319.58%, driving activity in the biopharmaceutical sector, benefiting Sonnet BioTherapeutics with a rise in stock price.

2. On May 15, analysts expected no change in Sonnet's quarterly revenue but gave a "Buy" rating, with a target price far above the current price, boosting market confidence.

3. On June 9, the active market in the innovative drug sector spread positive sentiment among pharmaceutical stocks, with Sonnet BioTherapeutics' stock price rising due to speculative trading.

Stocks with High Trading Volume in the Industry

ProKidney rose 51.21%, with a trading volume of 824 million. Based on recent important news:

1. On July 8, ProKidney announced the Phase II results of its REGEN-007 trial, showing that Rilparencel significantly improved the eGFR slope in chronic kidney disease patients, with no serious adverse events observed, leading to a 51.21% increase in stock price.

2. On July 8, the company stated that the results of the REGEN-007 trial enhanced its confidence in the design of the Phase III PROACT 1 trial, expecting the FDA to expedite the approval of Rilparencel.

3. On July 9, ProKidney announced that its management team would attend an important meeting, further boosting market confidence.

Calidi Biotherapeutics rose 270.12%. Based on recent important news:

1. On July 8, Calidi Biotherapeutics announced that it was mentioned in an editorial published by NetworkNewsWire, increasing market attention and significantly boosting its stock price.

2. On July 9, JP Morgan released a report that, although primarily focused on Hong Kong real estate, mentioned market interest in innovative financing methods, indirectly affecting investment sentiment in the biotechnology sector.

3. On July 8, Calidi Biotherapeutics' stock trading volume significantly increased, indicating enhanced investor confidence in its future development.

Abbvie fell 0.05%, with increased trading volume. Based on recent important news:

1. On July 9, analysts noted that Abbvie was not on the recommended list, leading to a decline in investor confidence and a slight drop in stock price.

2. On July 8, advancements in CAR-T cell therapy in the field of autoimmune diseases could impact Abbvie's market competitiveness.

3. On July 7, the high learning barriers in the innovative drug industry led to increased market volatility